Literature DB >> 8505552

An MTT-based method for the in vivo quantification of myotoxic activity of snake venoms and its neutralization by antibodies.

B Lomonte1, J M Gutiérrez, M Romero, J Núñez, A Tarkowski, L A Hanson.   

Abstract

The reduction of the tetrazolium compound MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide) was used as the basis for the development of a simple method for the quantitative estimation of metabolically active skeletal muscle tissue remaining after in vivo venom-induced myonecrosis. Using the venom of the snake Micrurus nigrocinctus as a potent myotoxic agent, this MTT-based technique was evaluated in comparison with available methods based on the measurement of creatine kinase (CK) activity, and a quantitative histological technique considered as a reference. Homogenates of the gastrocnemius muscle prepared in the presence of 1% Triton X-100 reduced MTT and this activity correlated closely with the number of viable cells in the tissue, as determined by histological evaluation. After venom injection, residual MTT-reducing activity of muscle homogenates showed higher correlation to the myonecrosis index obtained by histological analysis, than residual muscle CK activity. Using the new MTT-based assay, the ability of an anti-M. nigrocinctus equine antivenom to neutralize venom myotoxins was studied. The myotoxic activity of the venom was completely neutralized using 4 ml antivenom/mg venom, with a 50% effective dose (ED50) value of about 2.5 ml/mg. The MTT-based method described should be useful in the estimation and standardization of anti-myotoxic potency of antivenoms, and in the screening of other neutralizing agents, as a convenient and reliable alternative to the time-consuming quantitative histological methods.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8505552     DOI: 10.1016/0022-1759(93)90299-m

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  6 in total

1.  Macrophage activation, phagocytosis and intracellular calcium oscillations induced by scorpion toxins from Tityus serrulatus.

Authors:  V L Petricevich; E Reynaud; A H Cruz; L D Possani
Journal:  Clin Exp Immunol       Date:  2008-12       Impact factor: 4.330

2.  Inflammatory mediators release in urine from mice injected with Crotalus durissus terrificus venom.

Authors:  A Hernández Cruz; L Barbosa Navarro; R Z Mendonça; V L Petricevich
Journal:  Mediators Inflamm       Date:  2011-11-29       Impact factor: 4.711

3.  Alkylation of histidine residues of Bothrops jararacussu venom proteins and isolated phospholipases A2: a biotechnological tool to improve the production of antibodies.

Authors:  C L S Guimarães; S H Andrião-Escarso; L S Moreira-Dill; B M A Carvalho; D P Marchi-Salvador; N A Santos-Filho; C A H Fernandes; M R M Fontes; J R Giglio; B Barraviera; J P Zuliani; C F C Fernandes; L A Calderón; R G Stábeli; F Albericio; S L da Silva; A M Soares
Journal:  Biomed Res Int       Date:  2014-05-11       Impact factor: 3.411

4.  In vitro antiplasmodial activity of phospholipases A2 and a phospholipase homologue isolated from the venom of the snake Bothrops asper.

Authors:  Juan Carlos Quintana Castillo; Leidy Johana Vargas; Cesar Segura; José María Gutiérrez; Juan Carlos Alarcón Pérez
Journal:  Toxins (Basel)       Date:  2012-12-14       Impact factor: 4.546

5.  Crotalus durissus terrificus venom interferes with morphological, functional, and biochemical changes in murine macrophage.

Authors:  Anselmo Hernández Cruz; Ronaldo Z Mendonça; Vera L Petricevich
Journal:  Mediators Inflamm       Date:  2005-12-14       Impact factor: 4.711

6.  Inflammasome Activation Induced by a Snake Venom Lys49-Phospholipase A2 Homologue.

Authors:  Charles Nunes Boeno; Mauro Valentino Paloschi; Jéssica Amaral Lopes; Weverson Luciano Pires; Sulamita da Silva Setúbal; Jaína Rodrigues Evangelista; Andreimar Martins Soares; Juliana Pavan Zuliani
Journal:  Toxins (Basel)       Date:  2019-12-31       Impact factor: 4.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.